Literature DB >> 27450455

Pathogenesis of amyotrophic lateral sclerosis.

Sarah Morgan1, Richard W Orrell2.   

Abstract

INTRODUCTION: Amyotrophic lateral sclerosis (ALS) or motor neuron disease is a rapidly progressive neurodegenerative disorder. The primary involvement is of motor neurons in the brain, spinal cord and peripherally. There is secondary weakness of muscles and primary involvement of other brain regions, especially involving cognition. SOURCES OF DATA: Peer-reviewed journal articles and reviews. PubMed.gov AREAS OF AGREEMENT: The pathogenesis of ALS remains largely unknown. There are a wide range of potential mechanisms related to neurodegeneration. An increasing number of genetic factors are recognized. AREAS OF CONTROVERSY: There remains controversy, or lack of knowledge, in explaining how cellular events manifest as the complex human disease. There is controversy as to how well cellular and animal models of disease relate to the human disease. GROWING POINTS: Large-scale international collaborative genetic epidemiological studies are replacing local studies. Therapies related to pathogenesis remain elusive, with the greatest advances to date relating to provision of care (including multidisciplinary management) and supportive care (nutrition and respiratory support). AREAS TIMELY FOR DEVELOPING RESEARCH: The identification of C9orf72 hexanucleotide repeats as the most frequent genetic background to ALS, and the association with frontotemporal dementia, gives the potential of a genetic background against which to study other risk factors, triggers and pathogenic mechanisms, and to develop potential therapies.
© The Author 2016. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  amyotrophic lateral sclerosis; genetics; pathogenesis; treatment

Mesh:

Substances:

Year:  2016        PMID: 27450455     DOI: 10.1093/bmb/ldw026

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  40 in total

Review 1.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

Review 2.  TDP-43 and Cytoskeletal Proteins in ALS.

Authors:  Moritz Oberstadt; Joseph Claßen; Thomas Arendt; Max Holzer
Journal:  Mol Neurobiol       Date:  2017-05-02       Impact factor: 5.590

3.  NLRP3 Inflammasome Activation in a Transgenic Amyotrophic Lateral Sclerosis Model.

Authors:  Agnese Gugliandolo; Sabrina Giacoppo; Placido Bramanti; Emanuela Mazzon
Journal:  Inflammation       Date:  2018-02       Impact factor: 4.092

Review 4.  Unravelling the potential of gut microbiota in sustaining brain health and their current prospective towards development of neurotherapeutics.

Authors:  Ankita Banerjee; Lilesh Kumar Pradhan; Santosh Chauhan; Pradyumna Kumar Sahoo; Kautilya Kumar Jena; Nishant Ranjan Chauhan; Saroj Kumar Das
Journal:  Arch Microbiol       Date:  2021-03-24       Impact factor: 2.552

5.  Nerve Growth Factor is a Potential Treated Target in Tg(SOD1*G93A)1Gur Mice.

Authors:  Zhenzhen Xu; Jianxiang Jiang; Shengyuan Xu; Zunchun Xie; Pei He; Shishi Jiang; Renshi Xu
Journal:  Cell Mol Neurobiol       Date:  2020-11-24       Impact factor: 5.046

6.  The expression discrepancy and characteristics of long non-coding RNAs in peripheral blood leukocytes from amyotrophic lateral sclerosis patients.

Authors:  Yujiao Yu; Dejiang Pang; Chunyu Li; Xiaojing Gu; Yongping Chen; Ruwei Ou; Qianqian Wei; Huifang Shang
Journal:  Mol Neurobiol       Date:  2022-04-02       Impact factor: 5.590

Review 7.  The Impact of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis.

Authors:  Jiantao Zhao; Xuemei Wang; Zijun Huo; Yanchun Chen; Jinmeng Liu; Zhenhan Zhao; Fandi Meng; Qi Su; Weiwei Bao; Lingyun Zhang; Shuang Wen; Xin Wang; Huancai Liu; Shuanhu Zhou
Journal:  Cells       Date:  2022-06-28       Impact factor: 7.666

8.  CYP1A2 rs762551 polymorphism and risk for amyotrophic lateral sclerosis.

Authors:  Vasileios Siokas; Emmanouil Karampinis; Athina-Maria Aloizou; Alexios-Fotios A Mentis; Panagiotis Liakos; Dimitra Papadimitriou; Ioannis Liampas; Grigorios Nasios; Dimitrios P Bogdanos; Georgios M Hadjigeorgiou; Efthimios Dardiotis
Journal:  Neurol Sci       Date:  2020-06-26       Impact factor: 3.307

Review 9.  Cellular and physiological functions of C9ORF72 and implications for ALS/FTD.

Authors:  Weilun Pang; Fenghua Hu
Journal:  J Neurochem       Date:  2020-12-18       Impact factor: 5.372

Review 10.  Aberrant NLRP3 Inflammasome Activation Ignites the Fire of Inflammation in Neuromuscular Diseases.

Authors:  Christine Péladeau; Jagdeep K Sandhu
Journal:  Int J Mol Sci       Date:  2021-06-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.